Optiscan has been featured in Stockhead, The Australian, and across 11 additional News Corp mastheads following the announcement of a major milestone: the successful completion of the Minimum Viable Product (MVP) for its cloud-based telepathology streaming platform.

The coverage highlights how the platform—developed in partnership with Canadian firm Prolucid Technologies—integrates Optiscan’s proprietary confocal imaging technology to enable real-time collaboration between clinicians and pathologists, regardless of location. It allows for secure, high-resolution live streaming, annotation, report generation, and post-session review—delivering a powerful new digital pathology tool that removes traditional geographic and workflow barriers.

Described as a “game changer for global digital pathology,” the solution holds particular promise for regional, rural, and remote healthcare, where timely access to pathology expertise can be limited. It represents a key step forward in Optiscan’s broader mission to transform clinical decision-making through real-time imaging and remote collaboration.

The next phase of the project will focus on real-world validation and preparing for broader clinical deployment.

Stockhead – Watch the full segment here
The Australian – Watch the full segment here